<DOC>
	<DOCNO>NCT00085969</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy 28-day regimen exenatide ( AC2993 ) , give monotherapy subject type 2 diabetes mellitus .</brief_summary>
	<brief_title>Effect Exenatide Monotherapy Glucose Control Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Subject type 2 diabetes mellitus treat diet exercise modification alone combination one oral antidiabetic agent longer 4 year . Subject clinically significant history presence follow condition : ( ) Hepatic disease , ( b ) Renal disease , ( c ) Central nervous system disease , ( ) Gastrointestinal disease ( e ) Pulmonary disease ( f ) Hematologic disease . Subject currently treat follow excluded medication : ( ) Metformin/sulfonylurea combination therapy ( b ) Thiazolidinediones ( c ) Insulin outpatient therapy ( ) Regular use drug directly affect gastrointestinal motility ( e ) Regular use systemic corticosteroid oral , intravenous ( IV ) , intramuscular ( IM ) route , potent , inhale , intrapulmonary , intranasal steroid know high rate systemic absorption ( f ) Regular use medication addictive potential opiate , narcotic tranquilizer ( g ) Antineoplastic agent ( h ) Transplantation medication ( ) Prescription weightloss medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>diabetes</keyword>
	<keyword>exenatide</keyword>
	<keyword>Amylin</keyword>
	<keyword>Lilly</keyword>
</DOC>